Osteoporosis (OP) is one of the most serious diseases in the modern world, and OP patients
frequently suffer from fragility fractures in the hip, spine and wrist, resulting in a limited quality of life. Although
bisphosphonates (BPs) are the most effective class of anti-bone-resorptive drugs currently available and the most
commonly prescribed for the clinical treatment of OP, they are known to cause serious side effects such as
bisphosphonate-related osteonecrosis of the jaw. Novel therapeutic materials that can replace the use of BPs have
therefore been developed.